The first participant in Europe has joined the PrevenTRON study at our site in Aberdeen, marking an important milestone for Alzheimer’s research in Scotland.
The European first highlights what can be achieved when scientific expertise, research infrastructure and effective participant recruitment come together. For Scottish Brain Sciences (SBS), it is also an encouraging demonstration of the research capability being built in Scotland.
Studying Alzheimer’s disease before symptoms appear
PrevenTRON is a global Phase III clinical study sponsored by Roche. It is evaluating an investigational treatment in people who do not have memory or thinking problems but are at risk of progressing to symptomatic Alzheimer’s disease.
The study is investigating whether treatment before symptoms appear could delay or prevent their onset. It is not yet known whether the investigational treatment will achieve this; the purpose of the study is to answer that question.
Building Scotland’s capacity for international research
Finding and engaging the right participants is one of the biggest challenges facing clinical research. This is particularly important as Alzheimer’s research moves towards identifying and studying people earlier in the disease process.
SBS has been developing the capability to support this work in Scotland, bringing together research expertise, clinical facilities and participant recruitment. The milestone in Aberdeen demonstrates how these elements can help deliver ambitious international brain health studies.
It also reflects a wider ambition: to make Scotland an attractive place for international research while giving people here opportunities to contribute to studies that could shape the future of Alzheimer’s care.
Recognising the people behind the milestone
This achievement reflects the work of the SBS team and the generosity of the people who choose to take part in research. Their contribution makes studies such as PrevenTRON possible.
We are proud of the team who helped reach this milestone and grateful to our research participants for the part they play in advancing understanding of brain health.





